Peach Bowl LegACy Fund

We are pleased to announce a Request for Proposal (RFP) for the Peach Bowl LegACy Fund. The purpose of this RFP is to enhance Children’s Healthcare of Atlanta (Children’s) and the Aflac Cancer Center’s ability to open clinical trials for children, adolescents and young adults with pediatric cancers. This includes the development of novel drugs, devices and treatment strategies. The overall goal is to ensure that high-priority novel agents, devices and treatments can be tested in patients in a more rapid manner.

The Letter of Intent (two pages maximum) will be due on Friday, June 4, by 5 PM EST. All LOIs will be evaluated to determine if projects can move forward with the application process. Notifications will be sent to the PI by Monday, June 7.

Please email with any questions regarding the Letter of Intent, appropriateness of a specific proposal for this RFP or any other questions regarding the process.

Download RFP

RFP Announcement - 05/10/2021
Letter of Intent Due - 06/4/2021
Application Released - 6/7/2021
Application Due - 7/30/2021
Notification of Winners - October 2021

Recent Recipients

PI: Bree Eaton, MD

Co-PI(s): Hyunsuk Shim, PhD (Winship) and Claire Mazaewski, MD (Aflac Cancer Center)

Project Title: Spectroscopic MRI for the management of pediatric high-grade glioma patients


PI: Edwin Horwitz, MD, PhD

Co-PI(s): Muna Qayed, MD, MSc

Project Title: Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease after Allogeneic Hematopoietic Cell Transplantation for Patients with Hematologic Malignancies and Myelodysplasia

PI: Kelly Goldsmith, MD

Co-PI: Trent Spencer, PhD

Project Title: A Phase I Study of Allogeneic Ex Vivo Expanded Gamma Delta (γδ) T Cells in Combination with Dinutuximab, Temozolomide, and Zoledronate in Children with Refractory or Relapsed Neuroblastoma

PI: Tobey MacDonald, MD

Co-PI: Kavita Dhodapkar, MD

Project Title: AflacST1901 A Phase I Study of WP1066 in Children with Refractory and Progressive or Recurrent Malignant Brain Tumors

PI: Melinda Pauly, MD

Co-PI(s): Thomas Alexander, MD, MPH (UNC), William G. Blum, MD (Emory), Joshua Zeidner, MD (UNC)

Project Title: An Open-Label Evaluation Phase 1 Trial of the Safety and Pharmacokinetics of MRX-2843 in Adolescents and Adults with Relapsed/Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Mixed Phenotype Acute Leukemia

PI: Kathryn Sutton, MD

Co-PI: W. Thomas Cash, MD, MSc

Project Title: A Maintenance Protocol of Sirolimus in Combination with Metronomic Chemotherapy in Children with High-Risk Solid Tumors

PI: Kirsten Williams, MD

Co-PI: Muna Qayed, MD, MSc

Project Title: CD19/22 CARPOOL: Phase I trial of CD19/22 Chimeric Antigen Receptor Protocol with Objective of Tolerability in relapsed/refractory B-ALL